Biotechnology company Anixa Biosciences, Inc. (ANIX) announced Wednesday that it has entered into a joint development agreement with Cleveland Clinic to develop novel vaccines for various cancer types.Anixa currently collaborates with Cleveland Clinic on breast cancer and ovarian cancer vaccinesCleveland Clinic is currently conducting a Phase 1 clinical trial targeting triple negative breast cancer (TNBC), the most aggressive and lethal form of breast cancer, and an ovarian cancer vaccine is in pre-clinical development in collaboration with the National Cancer Institute..

生物技术公司Anixa Biosciences，Inc.（ANIX）周三宣布，已与克利夫兰诊所（Cleveland Clinic）签订联合开发协议，开发针对各种癌症类型的新型疫苗。Anixa目前与克利夫兰诊所合作研究乳腺癌和卵巢癌疫苗水平诊所目前正在进行一项针对三阴性乳腺癌（TNBC）的1期临床试验，三阴性乳腺癌是最具侵袭性和致命性的乳腺癌形式，卵巢癌疫苗正在与国家癌症研究所合作进行临床前开发。。

The vaccines focus on a novel scientific mechanism never used before in a cancer vaccine. The vaccines were developed at Cleveland Clinic and licensed to Anixa Biosciences. Cleveland Clinic is entitled to royalties and other commercialization revenues from the Company.The research under this new JDA will be led at Cleveland Clinic by Thaddeus Stappenbeck, Department Chair of Inflammation and Immunity, and will include Justin Johnson, one of the co-inventors of the breast and ovarian cancer vaccines along with the late Vincent Tuohy.

这些疫苗专注于一种从未用于癌症疫苗的新型科学机制。这些疫苗是在克利夫兰诊所开发的，并获得了Anixa Biosciences的许可。克利夫兰诊所有权从该公司获得版税和其他商业化收入。这项新的JDA研究将由克利夫兰诊所炎症与免疫系主任Thaddeus Stappenbeck领导，其中包括乳腺癌和卵巢癌疫苗的联合发明者之一Justin Johnson以及已故的Vincent Tuohy。

For comments and feedback contact: editorial@rttnews.comBusiness News.

如需评论和反馈，请联系：editorial@rttnews.comBusiness新闻。

Biotech Stocks Facing FDA Decision In April 2024

2024年4月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision in March 2024

2024年3月美国食品和药物管理局（FDA）决定生物技术股

Biotech Stocks Facing FDA Decision In November 2023

2023年11月美国食品和药物管理局（FDA）决定生物技术股